Davy James, Associate Editor

Researchers find interventions targeting mental health problems and substance abuse can improve treatment outcomes.

Gary Rice, RPh, MS, MBA, vice president of clinical services at Diplomat Specialty Pharmacy discusses effective counseling of rheumatoid arthritis patients on biologic DMARD therapy.

Bill Barre, RPh, vice president of business development at MedImpact Healthcare Systems, discusses the questions specialty providers need to address to reach consumers in the changing health care landscape.

Deborah Cmielewski, Esq., vice president and general counsel at Armada Health Care, discusses key issues regarding HI-Tecj/HIPAA legislation for specialty pharmacies.

Cardiovascular risk related to severity of inflammation, but not associated with disease duration.

Leigh Ann Bruhn, director of Avalere Health, discusses how specialty pharmacies can help achieve the goals of accountable care groups.

The United States stands to be a key player in the global oncology biosimilars market, which is predicted to generate up to $12 billion in revenue by 2020.

Michael Einodshofer, RPh, MBA, senior director of specialty strategy and innovation at Walgreens, discusses the potential impact of specialty medications on overall drug spending.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses emerging trends in the treatment of cancer that specialty pharmacies need to be aware of.

Shannon Ambrose, senior director of Specialty Solutions at Prime Therapeutics, discusses the factors that negatively impact medication adherence for specialty drugs.

Global oncology trend report finds that increased use of hospital outpatient facilities shifts cost burden to patients.

Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.

Pharmacists can assist patients with rheumatoid arthritis in overcoming challenges to adherence.

Jeremy Schafer, PharmD, MBA, Senior Director of Specialty Solutions and Manufacturer Relations at Prime Therapeutics, discusses new developments in medication adherence for specialty pharmacy.

Mitra Habibi, PharmD, a clinical pharmacist at the University of Illinois Hospital and Health Sciences System, discusses challenges for specialty pharmacy in the management of patients with multiple sclerosis.

Donna M. Smith, PharmD, director of clinical affairs at Avella Specialty Pharmacy discusses developments in the treatment of lung cancer that specialty pharmacies need to be aware of.

Catamaran Corporation Senior Vice President of Pharmacy Operations and Industry Albert Thigpen discusses the impact from the high cost of specialty medications on overall drug spending in 2014.

Role of specialty pharmacies in treatment of multiple sclerosis discussed during annual Armada summit.

Emerging therapies and the role of specialty pharmacies in the treatment of non-small cell lung cancer were discussed during a continuing education session at the annual Armada summit.

CVS Caremark specialty pharmacy executive discusses the evolution of a patient-centered health care ecosystem.

The cost of specialty drugs is driving increases in overall unit cost, according to an annual Catamaran Corporation report.

Author and consultant Myrtle Potter told attendees of the Armada Specialty Pharmacy Summit that specialty pharmacies need to demonstrate their value to capitalize on the changing health care environment.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.

Research suggests salaried physicians practice in the same manner as those reimbursed by fee-for-service methodology.

Armada Health Care celebrates the 10th anniversary of its annual specialty pharmacy conference.

Innovative new specialty drugs helped push total drug spending to $329.2 billion in 2013.

Celgene's apremilast (Otezla) was found to alleviate joint pain and inflammation during clinical trials.

CVS Caremark report projects that transition of specialty drugs from the medical benefit to the pharmacy benefit could provide significant cost relief to payers.